Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Zhipeng Yang

Podiatrist, Foot & Ankle Surgery Kansas City, KS Doctor of Podiatric Medicine

NPI 1821522962 CMS profile 7423766

8919 Parallel Pkwy Ste 555, Kansas City, KS 66112

Open in the dashboard

General payments

$25,037

194 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zhipeng Yang of Kansas City, KS is reported in the CMS Open Payments database as having received $25,037 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,368 24
2024 General $3,604 38
2023 General $3,956 50
2022 General $7,036 39
2021 General $9,021 40
2020 General $53 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zhipeng Yang
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Zhipeng Yang were reported at $1,368. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Zhipeng Yang Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $53 $191 $62–$691 $114
2021 $9,021 $329 $104–$1,341 $132
2022 $7,036 $419 $125–$1,611 $149
2023 $3,956 $377 $128–$1,164 $160
2024 $3,604 $394 $134–$1,168 $164
2025 $1,368 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Titan Surgical Group, LLC $6,173 8 payments
  2. Paragon 28, Inc. $4,758 14 payments
  3. Stryker Corporation $3,682 37 payments
  4. Treace Medical Concepts, Inc. $2,631 13 payments
  5. Orthofix Medical, Inc. $1,934 15 payments
  6. Medline Industries, Inc. $1,102 9 payments
  7. Medical Device Business Services, Inc. $1,026 6 payments
  8. Arthrex, Inc. $903 11 payments
  9. Smith+Nephew, Inc. $480 18 payments
  10. Organogenesis Inc. $438 9 payments
  11. Other $1,912 54 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Travel and Lodging $12,800 49 payments
  2. Food and Beverage $6,237 140 payments
  3. Education $6,000 5 payments
Products named General payments · program years 2020–2025
  1. MEDLINE UNITE $4,251 32 payments
  2. Product Portfolio $2,280 7 payments
  3. TrueLok $1,753 11 payments
  4. Lapiplasty System Y $1,641 7 payments
  5. PROPHECY $1,184 4 payments
  6. APEX 3D $915 3 payments
  7. LAPIPLASTY SYSTEM Foot And Ankle $809 4 payments
  8. INBONE $757 10 payments
  9. HOFFMANN $734 3 payments
  10. GORILLA $651 1 payment
  11. Other $6,662 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

270

Median for Podiatry: 160

Drug cost

$4,239

Median for Podiatry: $2,368

Branded share of claims

54.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 93 $2,191
Ciclopirox Generic 34 $1,136
Gabapentin Generic 59 $455
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 41 $266
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $119
Tramadol Hcl Generic 19 $51
Meloxicam Generic 12 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$99,291

Of which drugs: $156

Medicare patients

371

Average age 74

Services billed

1,912

220 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 42%
Chronic kidney disease 34%
Depression 28%
Ischemic heart disease 26%
Atrial fibrillation 20%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 37 169 $124
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 42 188 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $27
$27 — —
Kimyrsa
  • Melinta Therapeutics, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record